The LCN2 gene produces a protein within the lipocalin superfamily and has been found to be expressed highly in early-stage colorectal cancer, but is downregulated significantly in metastatic or advanced-stage colorectal cancer, which may suggest that the MTD-treated cells are not only transitioning into a more mesenchymal phenotype but are also significantly more aggressive [40]. This evidence concerns the gene LCN2 and colorectal cancer.